a cohort study for the evaluation of the use of neutralizing monoclonal SARS-CoV-2 antibodies and antiviral agents
Phase 1
- Conditions
- COVID-19Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- EUCTR2021-005051-37-NL
- Lead Sponsor
- Amsterdam University Medical Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
-All patients that are treated with neutralizing SARS-CoV-2 antibodies and other antivirals against or as prevention of SARS-CoV-2 as standard of care.
-Patients have to aged = 18 y
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 1000
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 1000
Exclusion Criteria
-No informed consent is provided by the patient (part II)
-Patients not suitable to fulfil study procedures
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method